PMID- 20354457
OWN - NLM
STAT- MEDLINE
DCOM- 20100812
LR  - 20100427
IS  - 1556-1380 (Electronic)
IS  - 1556-0864 (Linking)
VI  - 5
IP  - 5
DP  - 2010 May
TI  - The influence of sex on efficacy, adverse events, quality of life, and delivery 
      of treatment in National Cancer Institute of Canada Clinical Trials Group 
      non-small cell lung cancer chemotherapy trials.
PG  - 640-8
LID - 10.1097/JTO.0b013e3181d40a1b [doi]
AB  - BACKGROUND: Female sex is a favorable prognostic factor in lung cancer. In 
      small-cell lung cancer, women have been shown to experience greater toxicity from 
      chemotherapy, but there are few studies of sex-related toxicity in non-small cell 
      lung cancer (NSCLC). PATIENTS AND METHODS: This retrospective analysis evaluated 
      the effect of sex on efficacy, adverse events (AEs), dose intensity (DI), and 
      quality of life (QoL) in three phase III NSCLC trials conducted by the National 
      Cancer Institute of Canada Clinical Trials Group; BR.10 (adjuvant chemotherapy), 
      BR.14, and BR.18 (first-line advanced disease). Only patients with National 
      Cancer Institute of Canada Clinical Trials Group data were included, and patients 
      in the BR.10 observation arm were excluded. RESULTS: Of 1,108 patients analyzed, 
      29% were female. On study entry, women were less likely to be overweight or obese 
      (40% versus 51%, p < 0.0001), more likely to have adenocarcinoma (70% versus 44%, 
      p < 0.0001), and less likely to be anemic at baseline (29% versus 55%, p < 
      0.0001) or have medical comorbidities. There were no significant differences in 
      response rate to chemotherapy (27% versus 31%, p = 0.44 [excluding BR.10]), grade 
      3 or 4 AEs, DI, or QoL between sexes, although women reported more nausea and 
      vomiting of any grade (77% versus 66%, p = 0.0004). In multivariate analysis, 
      women had longer progression-free survival than men (hazard ratio 0.83, 95% 
      confidence interval 0.71-0.97, p = 0.02) but not overall survival (hazard ratio 
      0.89, 95% confidence interval 0.75-1.05, p = 0.17). CONCLUSION: Women demonstrate 
      modestly longer progression-free survival than men in chemotherapy-treated NSCLC, 
      with no differences observed in response rates, serious AEs, or QoL.
FAU - Wheatley-Price, Paul
AU  - Wheatley-Price P
AD  - Princess Margaret Hospital/University Health Network, University of Toronto, 
      Toronto, Canada. pwheatleyprice@toh.on.ca
FAU - Le Maitre, Aurelie
AU  - Le Maitre A
FAU - Ding, Keyue
AU  - Ding K
FAU - Leighl, Natasha
AU  - Leighl N
FAU - Hirsh, Vera
AU  - Hirsh V
FAU - Seymour, Lesley
AU  - Seymour L
FAU - Bezjak, Andrea
AU  - Bezjak A
FAU - Shepherd, Frances A
AU  - Shepherd FA
CN  - NCIC Clinical Trials Group
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Thorac Oncol
JT  - Journal of thoracic oncology : official publication of the International 
      Association for the Study of Lung Cancer
JID - 101274235
SB  - IM
MH  - Adenocarcinoma/drug therapy/*mortality/pathology
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Canada
MH  - Carcinoma, Non-Small-Cell Lung/drug therapy/*mortality/pathology
MH  - Carcinoma, Squamous Cell/drug therapy/*mortality/pathology
MH  - Chemotherapy, Adjuvant
MH  - Clinical Trials, Phase III as Topic
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*mortality/pathology/therapy
MH  - Male
MH  - Neoplasm Staging
MH  - *Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Retrospective Studies
MH  - Sex Factors
MH  - Treatment Outcome
EDAT- 2010/04/01 06:00
MHDA- 2010/08/13 06:00
CRDT- 2010/04/01 06:00
PHST- 2010/04/01 06:00 [entrez]
PHST- 2010/04/01 06:00 [pubmed]
PHST- 2010/08/13 06:00 [medline]
AID - S1556-0864(15)32137-7 [pii]
AID - 10.1097/JTO.0b013e3181d40a1b [doi]
PST - ppublish
SO  - J Thorac Oncol. 2010 May;5(5):640-8. doi: 10.1097/JTO.0b013e3181d40a1b.